Dechra Share Price (DPH)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Dechra Pharmaceuticals	LSE:DPH	London	Ordinary Share	GB0009633180	ORD 1P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	+10.00p	+0.58%	1,729.00p	1,728.00p	1,730.00p	1,729.00p	1,707.00p	1,715.00p	52,499	13:34:20

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	247.6	14.5	14.0	123.5	1,610.49

Dechra (DPH) Latest News

Dechra News

Date	Time	Source	Headline
06/7/2017	12:45	ALNCF	Alliance News Flash Headline
06/7/2017	08:46	ALNC	Dechra Pharmaceuticals Revenue Rises In "Strong" Financial Year
06/7/2017	07:00	UKREG	Dechra Pharmaceuticals PLC Trading Update & Notice of Annual Results
30/6/2017	10:10	UKREG	Dechra Pharmaceuticals PLC Total Voting Rights
22/6/2017	12:04	ALNC	DIRECTOR DEALINGS: Dechra CEO Sells GBP2.6 Million In Shares
22/6/2017	08:36	UKREG	Dechra Pharmaceuticals PLC Director/PDMR Shareholding
31/5/2017	15:39	UKREG	Dechra Pharmaceuticals PLC Total Voting Rights
18/5/2017	11:42	UKREG	Dechra Pharmaceuticals PLC Holding(s) in Company
03/5/2017	16:42	UKREG	Dechra Pharmaceuticals PLC Director/PDMR Shareholding
28/4/2017	14:27	UKREG	Dechra Pharmaceuticals PLC Total Voting Rights

More Dechra News

Dechra Takeover Rumours

Dechra (DPH) Share Charts

1 Year Dechra Chart

1 Month Dechra Chart

Intraday Dechra Chart

Dechra (DPH) Discussions and Chat

Dechra Forums and Chat

Date	Time	Title	Posts
30/6/2017	07:38	Dechra Pharmaceuticals Plc	322
10/3/2012	16:11	LOOKING TO BUY DECHRA PHARMACEUTICAL	88
10/3/2012	16:10	Dechra with Charts	9
10/3/2012	16:10	Dechra Pharmaceuticals PLC	1

Add a New Thread

Dechra (DPH) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
12:34:02	1,729.00	66	1,141.14	AT
12:34:02	1,729.00	74	1,279.46	AT
12:34:02	1,729.00	150	2,593.50	AT
12:30:47	1,728.00	90	1,555.20	AT
12:30:03	1,727.00	112	1,934.24	AT

View all Dechra trades in real-time

Dechra (DPH) Top Chat Posts

Date	Subject
20/7/2017 09:20	Dechra Daily Update: Dechra Pharmaceuticals is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker DPH. The last closing price for Dechra was 1,719p. Dechra Pharmaceuticals has a 4 week average price of 1,636p and a 12 week average price of 1,636p. The 1 year high share price is 1,970p while the 1 year low share price is currently 1,225p. There are currently 93,146,006 shares in issue and the average daily traded volume is 181,753 shares. The market capitalisation of Dechra Pharmaceuticals is £1,600,248,383.08. Read Full Thread Reply
12/7/2016 14:46	steeplejack: Consensus eps for the year to end June 2017 is for eps of around 51p,putting the stock on a prospective PE of 24,yielding 1.7% .With 20% growth anticipated in the 2016/17 year,the PEG ratio is an undemanding 1.2 Difficult to see the stock pushing ahead aggressively from here but with a full year of the US acquisitions to be accounted for, any sterling weakness could benefit the share price.This is a relatively illiquid,thin share market .The shares have a history of retrenching after a share price run but if fresh institutional buyers emerge,which is quite possible in these nervous markets,the stock could yet surprise on the upside. Read Full Thread Follow Reply
22/10/2010 21:34	gopher: This looks a fairly expensive purchase based on Sales/Profits. $42ml for a company turnover of $10m albeit with profits of $4ml; also up to a further $20ml if sales increase. Still what do I know as share price has risen but USA is a traditional acquisitions graveyard for british companies. Read Full Thread Follow Reply
22/4/2007 21:19	mallet3: DPH is one of the hidden gems that few people know about. It is an essential part of any portfolio. Good solid growth, decent divi yield, excellent mgmt, expanding markets, new territories and much more. Treating companion animals is a niche the big boys have not been to bothered with, leaving DPH the chance to make hay. The fact that Dresdner have picked up coverage means more people will be attracted to the company, which will do no harm to the share price. Just because the mkt cap is not huge it does not make a company like this a huge risk to invest in. I am looking forward to holding on for another four years of good solid defensive (but not pedestrian) growth!!! Read Full Thread Follow Reply
19/4/2006 18:50	shuisky: There has been a delay, and revenue streams forecasts from US approvals have had to be pushed further out. The share price was hit as a consequence. So short term your broker was right, but I hoped he advised you back in after the share had fallen! Frankly, I don't go for this kind of chopping & changing because you can very easily miss the move. The stock's undervalued, IMHO, and the recent fall made it even more undervalued. The selling creates an entry point opportunity, and those of us who are long term holders have preferred to top up at low levels. Does a delay in say 6 months for approval really make DPH undervalued at current levels? What's the worst that can happen here? The worst case scenario is that they don't get approval and you are left holding a cash-cow company generating 5-6% free cash flow, with low single digit growth prospects, but who still has the ability to increase margins by increasing pharma sales in Europe/UK. The downside is limited, and the upside is attractive. Read Full Thread Follow Reply
05/9/2005 11:56	the old codger: That's tomorrow - I must say I am impressed with the slow but inexorable progress of the share price in front of the figures - hopefully the figs will satisfy everyone and further progress will be seen. Great also to see so few posters here! IMHO DYOR TOC Read Full Thread Follow Reply
17/2/2005 12:14	lbo: BROKER RECOMMENDATIONS TODAY Evolution says buy Amstrad and add Dechra! Also The telegraph article on the 10th said! "Investors looking for a relatively uneventful but offbeat investment could do worse than plump for Dechra, the Yorkshire-based pharmaceuticals company. Dechra's share price has been on a steady trajectory upwards since January 2003 when it issued a profits warning. Its share price is trading at 198p, up 4½p yesterday, valuing the company at £100m. It has risen consistently thanks to generally positive results, an enduring market share and new products. Yesterday, it announced a further expansion in its range of veterinary products. One is Ovuplant a controlled-release synthetic hormone used to stimulate ovulation in horses. Another, for dogs, is a drug called Vetoryl and the company has launched a new capsule size for smaller pooches. The company has secured UK authorization of the product and will begin marketing it later this year. Vetoryl's UK sales currently stand at £1m a year, and management claim that the US market is 10 times bigger the drug has been granted a fast-track review by the US Food and Drug Administration. The company said in January that market conditions were improving. It expects to increase market share and deliver interim sales growth of 10pc. Analysts predict sales this year to climb to £198m, up from £187m last year. Adjusted profits are forecast to rise to £9.2m, up from £8.1m. This puts the shares on a forward rating of 16 times earnings, falling to 14.6 times in 2006. As with all pharma companies nothing is certain, but Dechra looks cheap. And it pays a dividend. Read Full Thread Follow Reply

Dechra share price data is direct from the London Stock Exchange

Your Recent History

LSE

GKP

Gulf Keyst..

LSE

QPP

Quindell

FTSE

UKX

FTSE 100

LSE

IOF

Iofina

GBPUSD

UK Sterlin..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P:32 V: D:20170720 12:50:08